

(b) if so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF ENERGY (SHRI VIKRAM MAHAJAN.): (a) and (b) Government of India have been following an integrated energy system policy for the country as a whole. The Sixth Five Year Plan recognises the need for formulation of an overall energy strategy. The elements of the energy strategy being followed are as follows: —

1. accelerated exploitation of domestic conventional energy resources—oil, coal and hydro and nuclear power;
2. management of oil demands;
3. energy conservation;
4. exploitation of renewable sources of energy like energy forestry and bio-gas, specially to meet the energy requirements of rural communities; and
- 5 intensification of research and development in emerging energy technologies.

Category of formulations	Claimed licensed capacity	Unit	Production during		
			1977-78	1978-79	1979-80
			(ending June)		
1. Liquids (Orals/parenterals)	1207	Kilo Ltrs.	2490	2956	3905
2. Tablets/Capsules	576	Mill Nos.	1604	1554	2077
3. Solids/Powders/Oints/Malt	134	Tonnes	547	665	1003

(c) In the interests of maximising production, Government have decided to recognise installed capacities in excess of licensed capacities in the case of a number of industries, including the drug industry. The recognition of the excess capacity of M/s. Glaxo as those of other drug companies will be governed by the Policy announced in this Ministry's Press Note Dated 17-10-1981. Action on any excess production beyond the permitted levels in

Exceeding of licensed capacity 1>y M/s. Glaxo Ltd.

781. SHRI JAGADISH JANI: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that M/s. Glaxo Ltd. have exceeded their licensed capacity for a large number of drug formulations;

(b) if so, what are the details thereof for the past three years; and

(c) what steps are being taken by Government to see that M/s. Glaxo Ltd. do not exceed their licensed capacity in future and what action his Ministry propose to take regarding unauthorised production?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) and (b) M/s. Glaxo Labs. (I) Ltd., on the basis of data made available in connection with the recognition of excess installed capacities of formulations, are observed to have exceeded their claimed licensed capacities in respect of the following categories: —

the future will be taken as per the Policy/provisions then in force.

Production of bulk drugs by M/s. Glaxo Ltd.

782. SHRI JAGADISH JANI: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that M/s. Glaxo Limited were not producing

21 bulk drugs out of 32 licensed to them during the past five years;

(b) if so, what steps have been taken by Government to revoke the industrial licences covering these 21 bulk drugs; and

(c) what steps are being taken to keep afloat pending proposals of M/s. Glaxo Limited in abeyance until they regularise their bulk drug manufacture?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) Yes

k Sir.

(b) A show-cause notice for revoking three licences covering 10 bulk drugs has already been issued. A final decision would be taken on receipt of the reply from the company. A condition is being stipulated in the approval for expansion of Betamethasone that four other Corticosteroids in that licence will be deleted from the licence. The remaining bulk drugs are covered by Industrial Licences which have been partially implemented.

(c) Applications for the manufacture of items received from companies are considered on merits. Action with reference to unimplemented Industrial Licence of the party, if any, are taken separately.

**Import of Triene for Betamethasone
by M/s. Glaxo**

783. SHRI JAGADISH JANI: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state;

(a) whether it is a fact that M/s. Glaxo Ltd. have reported, belatedly, the import of the intermediates triene during the past three years for the manufacture of betamethasone/derivatives;

(b) if so, when was this matter reported and whether this fact was disclosed to the BICP and in the compulsory cost audit of the company;

(c) what steps are being taken by Government to stop this irregular practice; and

(d) whether Government propose to send a notice to M/s. Glaxo under the Drug Prices Equalisation Account for the quantity of betamethasone/derivatives produced by them from triene?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) The imports of intermediates by M/s. Glaxo Laboratories (India) Limited for the production of Betamethasone during the last three years have already been furnished in reply to Rajya Sabha Starred Question No. 203 answered on 7th December, 1981.

(b) M/s. Glaxo Laboratories (India) Limited vide their letter dated 15th January, 1979 intimated that they have been encountering a serious problem at the micro-biological fermentation stage in 23 stage process of manufacture of Betamethasone as also some problems at two of the prior stages. This according to M/s. Glaxo resulted in their production coming down by approximately 33 per cent of the average output during the period October to December 1978 and also in substantial drop of yields. They indicated that they have taken steps to import Triene, the post fermentation stage drug intermediate for achieving normal production. The intimation of the above facts was given to my Ministry, DGTD and the Bureau of Industrial Costs and Prices. The fact concerning import of Triene by this company has been deindicated upon in the cost audit report of the year ending 30th June, 1979, 30th June, 1980 and 30th June, 1981. The practice of making available the cost Audit Reports to this Ministry has started from the current year.

(c) The Office of the Chief Controller of Imports and Exports is already considering suitable changes in the Policy concerning import of inter-